By immunohistochemistry, DAM is typically a desmin-positive myofibroblastic tumour (Figure 1F) with variable expression of HMGA2 [14], α-smooth-muscle actin (from 27% to 95% of cases) and CD34 (from 17% to 50%) [13,15]. This evidence concerns the gene DES and neoplasm.